HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf CEO Signs Five-Year Contract Following Strong 2013

This article was originally published in The Rose Sheet

Executive Summary

Beiersdorf CEO Stefan Heidenreich has signed a new five-year contract extending his tenure through 2019, the Hamburg, Germany-based firm announces in conjunction with the release of its preliminary Q4/full year 2013 results. Sales rose more than 7% organically to more than $8 billion, though the results on a nominal sales basis were weighted down by currency effects.

You may also be interested in...



Beiersdorf Shuffling Top Management As Nivea Growth Slows

Speculation has it that strategic disagreement between CEO Stefan Heidenreich and Beiersdorf’s controlling Herz family may be the reason for the exec’s planned departure at the end of 2018, if not earlier. The firm also welcomed a new CFO at the start of July after forecasting slowing growth for the remainder of fiscal 2018.

Beiersdorf CEO: Firm “On Track” For Growth In 2013

Increased market share among its Nivea, Eucerin and La Prairie brands helped drive Beiersdorf to a 6.5% increase in sales during the first half of 2013.

New Beiersdorf CEO Heidenreich Affirms: “We’re On The Right Track”

Beiersdorf is seeing early signs that its new business strategy and streamlining efforts are paying off. The firm’s first-quarter sales increased 6.9% to €1.53 billion, with strong performances from its NIVEA and Eucerin brands. Emerging markets were a source of growth, and new CEO Stefan Heidenreich vows to mend the firm’s leaky China business.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel